Cardiol Therapeutics Files Routine 6-K for News Release
Ticker: CRDL · Form: 6-K · Filed: Feb 15, 2024 · CIK: 1702123
Sentiment: neutral
Topics: Regulatory Filing, News Release, 6-K
Related Tickers: CRDL
TL;DR
**Cardiol Therapeutics just filed a routine 6-K to submit a news release, so keep an eye out for the actual news!**
AI Summary
Cardiol Therapeutics Inc., a foreign private issuer, filed a Form 6-K with the United States Securities and Exchange Commission on February 15, 2024. The purpose of this routine regulatory filing was to furnish a news release, designated as Exhibit 99.1, for the month of February 2024.
Why It Matters
This filing is a standard regulatory disclosure for foreign private issuers, informing investors that Cardiol Therapeutics Inc. has issued a news release, the content of which would provide updates on the company's operations or developments.
Risk Assessment
Risk Level: low — This 6-K is a procedural filing to submit a news release, not an event that inherently carries significant risk without knowing the content of the news release itself.
Key Players & Entities
- Cardiol Therapeutics Inc. (company) — registrant
- United States Securities and Exchange Commission (company) — regulator
- February 2024 (date) — period of report
FAQ
What company filed this Form 6-K?
Cardiol Therapeutics Inc. filed this Form 6-K.
What is the primary purpose of this 6-K filing?
The primary purpose of this 6-K filing is to submit a news release, identified as Exhibit 99.1.
What is the Commission File Number for Cardiol Therapeutics Inc.?
The Commission File Number for Cardiol Therapeutics Inc. is 001-40712.
When was this Form 6-K filed?
This Form 6-K was filed on February 15, 2024.
Under which form does Cardiol Therapeutics Inc. file its annual reports?
Cardiol Therapeutics Inc. files its annual reports under Form 20-F.
Filing Stats: 223 words · 1 min read · ~1 pages · Grade level 13.3 · Accepted 2024-02-15 07:30:17
Filing Documents
- form6k.htm (6-K) — 6KB
- exhibit99-1.htm (EX-99.1) — 10KB
- exhibit99-1xu001.jpg (GRAPHIC) — 8KB
- 0001062993-24-003270.txt ( ) — 28KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CARDIOL THERAPEUTICS INC. (Registrant) Date: February 15, 2024 By: /s/ Chris Waddick Chris Waddick Title: Chief Financial Officer